Frankly this is something our President might labe
Post# of 15624
(Total Views: 524)
Posted On: 10/06/2017 8:08:29 PM
Re: Bilo Selhi #11030
Frankly this is something our President might label false news, but it's really not, but it's not really important changes either. I don't know if their was a reason the company had to do it, but perhaps their was.
It would have been nice if they did an update at the same time and told us that the Phase 1 Safety Trial was being expanded, a new target date for the completion of the trial, which was mentioned for third quarter. We're clearly in the fourth quarter, so as long as they were making the change they could have changed that, but they didn't.
I don't know when, or if, they'll ever tell investors about the changes they've made in the safety trial. The only way they'll discuss any partnership that may be in play is if it comes to fruition. Companies always talk under confidentiality agreements, but that doesn't mean the company can say nothing to investors, it means that they can't say anything about their ongoing discussions. The status of a drug in trial is something a company can discuss in a quarterly, or a letter to shareholders, etc. Our company has issued both, yet not divulged any changes to the safety trial which hasn't been updated since it was put in the clinical trials database last November.
The laws may not force companies to divulge all that I'm suggesting, but other companies certainly do it, I'm sorry OWCP doesn't.
Gary
It would have been nice if they did an update at the same time and told us that the Phase 1 Safety Trial was being expanded, a new target date for the completion of the trial, which was mentioned for third quarter. We're clearly in the fourth quarter, so as long as they were making the change they could have changed that, but they didn't.
I don't know when, or if, they'll ever tell investors about the changes they've made in the safety trial. The only way they'll discuss any partnership that may be in play is if it comes to fruition. Companies always talk under confidentiality agreements, but that doesn't mean the company can say nothing to investors, it means that they can't say anything about their ongoing discussions. The status of a drug in trial is something a company can discuss in a quarterly, or a letter to shareholders, etc. Our company has issued both, yet not divulged any changes to the safety trial which hasn't been updated since it was put in the clinical trials database last November.
The laws may not force companies to divulge all that I'm suggesting, but other companies certainly do it, I'm sorry OWCP doesn't.
Gary
(0)
(0)